A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

BACKGROUND: There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. METHODS: A multicenter prospective phase II trial was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrini, Cinzia, Dodero, Anna, Chiappella, Annalisa, Monaco, Federico, Degl’Innocenti, Debora, Salvi, Flavia, Vitolo, Umberto, Argnani, Lisa, Corradini, Paolo, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830040/
https://www.ncbi.nlm.nih.gov/pubmed/27071522
http://dx.doi.org/10.1186/s13045-016-0266-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830040/
https://www.ncbi.nlm.nih.gov/pubmed/27071522
http://dx.doi.org/10.1186/s13045-016-0266-1

Ejemplares similares